Suzhou Zelgen Biopharmaceuticals Co., Ltd. More Details
Exceptional growth potential with adequate balance sheet.
Share Price & News
How has Suzhou Zelgen Biopharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 688266 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 688266's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 688266 underperformed the CN Biotechs industry which returned 32.5% over the past year.
Return vs Market: 688266 underperformed the CN Market which returned 24.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Suzhou Zelgen Biopharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Suzhou Zelgen Biopharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 688266 (CN¥59.87) is trading below our estimate of fair value (CN¥163.44)
Significantly Below Fair Value: 688266 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 688266 is unprofitable, so we can't compare its PE Ratio to the CN Biotechs industry average.
PE vs Market: 688266 is unprofitable, so we can't compare its PE Ratio to the CN market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 688266's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 688266 is overvalued based on its PB Ratio (8.4x) compared to the CN Biotechs industry average (6.4x).
How is Suzhou Zelgen Biopharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688266 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.3%).
Earnings vs Market: 688266 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 688266's is expected to become profitable in the next 3 years.
Revenue vs Market: 688266's revenue (48.2% per year) is forecast to grow faster than the CN market (17.9% per year).
High Growth Revenue: 688266's revenue (48.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688266's Return on Equity is forecast to be high in 3 years time (22.7%)
How has Suzhou Zelgen Biopharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 688266 is currently unprofitable.
Growing Profit Margin: 688266 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 688266 is unprofitable, and losses have increased over the past 5 years at a rate of 15% per year.
Accelerating Growth: Unable to compare 688266's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 688266 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.9%).
Return on Equity
High ROE: 688266 has a negative Return on Equity (-17.82%), as it is currently unprofitable.
How is Suzhou Zelgen Biopharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: 688266's short term assets (CN¥1.7B) exceed its short term liabilities (CN¥128.3M).
Long Term Liabilities: 688266's short term assets (CN¥1.7B) exceed its long term liabilities (CN¥87.6M).
Debt to Equity History and Analysis
Debt Level: 688266's debt to equity ratio (0.7%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 688266's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 688266 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 688266 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Suzhou Zelgen Biopharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 688266's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 688266's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 688266's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 688266's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 688266's dividend in 3 years as they are not forecast to pay a notable one for the CN market.
How experienced are the management team and are they aligned to shareholders interests?
Suzhou Zelgen Biopharmaceuticals has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Suzhou Zelgen Biopharmaceuticals Co., Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Suzhou Zelgen Biopharmaceuticals Co., Ltd.
- Ticker: 688266
- Exchange: SHSE
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥14.119b
- Shares outstanding: 240.00m
- Website: https://www.zelgen.com
Number of Employees
- Suzhou Zelgen Biopharmaceuticals Co., Ltd.
- No. 209, Chenfeng Road
- Jiangsu Province
Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers small molecule and recombinant protein drugs for the treat...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/17 09:20|
|End of Day Share Price||2021/04/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.